Equities Analysts Set Expectations for Lexicon Pharmaceuticals Inc.’s Q1 2017 Earnings (LXRX)
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) – Analysts at Wedbush reduced their Q1 2017 EPS estimates for shares of Lexicon Pharmaceuticals in a research note issued to investors on Wednesday. Wedbush analyst L. Moussatos now expects that the brokerage will earn ($0.63) per share for the quarter, down from their previous forecast of ($0.58). Wedbush has a “Buy” rating and a $33.00 price target on the stock. Wedbush also issued estimates for Lexicon Pharmaceuticals’ Q2 2017 earnings at ($0.59) EPS, Q3 2017 earnings at ($0.48) EPS, Q4 2017 earnings at ($0.51) EPS, FY2017 earnings at ($2.20) EPS and FY2018 earnings at ($1.01) EPS.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. The company earned $20.10 million during the quarter, compared to the consensus estimate of $12.36 million. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. Lexicon Pharmaceuticals’s revenue was up 5186.8% on a year-over-year basis. During the same period last year, the company earned ($0.27) earnings per share.
Several other brokerages also recently weighed in on LXRX. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, September 12th. Citigroup Inc. upped their target price on Lexicon Pharmaceuticals from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, September 12th. Stifel Nicolaus upped their target price on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research raised Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 3rd. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, September 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $20.93.
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 18.91 on Monday. The company’s market capitalization is $1.96 billion. The stock’s 50 day moving average price is $15.99 and its 200 day moving average price is $14.14. Lexicon Pharmaceuticals has a 52-week low of $7.65 and a 52-week high of $19.46.
Hedge funds have recently modified their holdings of the company. BlackRock Fund Advisors boosted its stake in shares of Lexicon Pharmaceuticals by 5.9% in the first quarter. BlackRock Fund Advisors now owns 2,322,113 shares of the biopharmaceutical company’s stock valued at $27,749,000 after buying an additional 129,969 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $2,194,000. DekaBank Deutsche Girozentrale boosted its stake in shares of Lexicon Pharmaceuticals by 15.9% in the second quarter. DekaBank Deutsche Girozentrale now owns 51,741 shares of the biopharmaceutical company’s stock valued at $735,000 after buying an additional 7,100 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Lexicon Pharmaceuticals by 66.3% in the second quarter. GSA Capital Partners LLP now owns 103,580 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 41,278 shares during the last quarter. Finally, Royce & Associates LP boosted its stake in shares of Lexicon Pharmaceuticals by 31.2% in the first quarter. Royce & Associates LP now owns 340,589 shares of the biopharmaceutical company’s stock valued at $4,070,000 after buying an additional 81,000 shares during the last quarter.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.